Full Text View
Tabular View
Study Results
Related Studies
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
This study has been completed.
Study NCT00322556   Information provided by CSL Behring

First Received on May 5, 2006.   Last Updated on September 27, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Agammaglobulinemia
IgG Deficiency
Common Variable Immunodeficiency
Additional conditions recognized in this trial
Immunologic Deficiency Syndromes
More general conditions related to this trial
Blood Protein Disorders
Dysgammaglobulinemia
Hematologic Diseases
Immune System Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Interventions listed in this trial
Immunoglobulins Intravenous (Human)
Additional drug interventions recognized in this trial
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
CSL Behring


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services